Privium Fund Management B.V. Has $5 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Privium Fund Management B.V. raised its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 34.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 397,650 shares of the biotechnology company's stock after buying an additional 102,850 shares during the quarter. Rocket Pharmaceuticals accounts for 1.1% of Privium Fund Management B.V.'s portfolio, making the stock its 19th largest position. Privium Fund Management B.V. owned about 0.44% of Rocket Pharmaceuticals worth $4,998,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of Rocket Pharmaceuticals by 22.8% in the third quarter. Wellington Management Group LLP now owns 11,242,144 shares of the biotechnology company's stock worth $207,642,000 after purchasing an additional 2,086,424 shares in the last quarter. State Street Corp raised its position in Rocket Pharmaceuticals by 11.6% during the third quarter. State Street Corp now owns 3,102,022 shares of the biotechnology company's stock valued at $57,294,000 after acquiring an additional 322,156 shares in the last quarter. Maverick Capital Ltd. raised its position in Rocket Pharmaceuticals by 4.8% during the third quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company's stock valued at $76,072,000 after acquiring an additional 190,360 shares in the last quarter. Westfield Capital Management Co. LP raised its position in Rocket Pharmaceuticals by 3.8% during the third quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company's stock valued at $83,001,000 after acquiring an additional 165,911 shares in the last quarter. Finally, Sovran Advisors LLC bought a new position in Rocket Pharmaceuticals during the fourth quarter valued at approximately $1,895,000. 98.39% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Rocket Pharmaceuticals Stock Performance

Rocket Pharmaceuticals stock traded down $0.14 during trading hours on Thursday, hitting $8.32. The stock had a trading volume of 1,182,331 shares, compared to its average volume of 992,648. The company has a 50-day moving average of $9.93 and a two-hundred day moving average of $13.72. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06. The company has a market cap of $887.16 million, a PE ratio of -3.03 and a beta of 1.03. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $28.67.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.06. On average, equities research analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RCKT. BMO Capital Markets began coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price objective on the stock. Scotiabank increased their price target on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. Wedbush began coverage on Rocket Pharmaceuticals in a report on Monday, December 30th. They set an "outperform" rating and a $32.00 price target on the stock. Needham & Company LLC lowered their price target on Rocket Pharmaceuticals from $52.00 to $42.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Finally, Canaccord Genuity Group lowered their price target on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.